{"id":530287,"date":"2021-08-23T07:03:06","date_gmt":"2021-08-23T11:03:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/"},"modified":"2021-08-23T07:03:06","modified_gmt":"2021-08-23T11:03:06","slug":"glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/","title":{"rendered":"Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on <i>iStent<\/i><sup>\u00ae<\/sup> Technologies<\/b><\/p>\n<p class=\"bwalignc\"><i>Supporting the Most Robust, Diverse and Longest-Term Body of Clinical Evidence for Any MIGS Technology<\/i><\/p>\n<p class=\"bwalignc\"><i>Multiple 5-, 6-, 7- and 8-Year Real-World Studies Published, Demonstrating Leading Efficacy &amp; Safety Across the Entire Glaucoma Disease Spectrum<\/i><\/p>\n<p class=\"bwalignc\"><i>Outcomes Reinforce the Powerful Benefit\/Risk Calculus of iStent Technologies\u2019 Micro-invasive, Tissue-Sparing Approach, Supporting the More Than 800,000 iStent Procedures Performed Globally to Date<\/i><\/p>\n<p>SAN CLEMENTE, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGlaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today an unprecedented clinical data milestone of 200 peer-reviewed publications highlighting the efficacy and safety of <i>iStent<sup>\u00ae<\/sup><\/i> technologies around the world. This achievement represents the largest, most diverse and longest-term body of clinical data for any MIGS procedure. Several points of note in this market-leading body of clinical evidence include:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nOver 20,000 eyes have been analyzed in a wide range of studies over nearly 20 years.\n<\/li>\n<li>\n183 publications detail independently conducted, investigator-initiated studies.\n<\/li>\n<li>\n11 studies are prospective, randomized, controlled trials (RCTs).\n<\/li>\n<li>\nMore than 50 of the publications highlight studies in a standalone glaucoma patient population, with 20 meta-analyses and 14 cost-effectiveness studies demonstrating payor and practice efficiency.\n<\/li>\n<li>\n15 publications analyze 4- to 8-year outcomes data, establishing the largest and longest-term follow up of any MIGS procedure.\n<\/li>\n<li>\nIndependent research from more than 20 countries has been published, demonstrating efficacy and safety in highly diverse patient populations with varying degrees of glaucoma (ocular hypertension through advanced\/refractory disease).\n<\/li>\n<li>\nFirst and only MIGS procedure to demonstrate improved patient quality of life from a pivotal trial.\n<\/li>\n<\/ul>\n<p>\nIn addition, the official publication of the World Glaucoma Association, the <i>Journal of Glaucoma<\/i>, selected a study on <i>iStent<\/i> and <i>iStent<\/i><i>inject<sup>\u00ae<\/sup><\/i> as its July 2021 Paper of the Month. In this systematic review and meta-analysis authored by Dr. Paul Healey, a total of 13 studies were analyzed to evaluate the independent effect of <i>iStent<\/i> and <i>iStent inject<\/i> without cataract surgery, including four randomized controlled trials and nine non-randomized (single-arm) studies providing data on 778 eyes. In eyes implanted with <i>iStent<\/i> devices, a weighted mean intraocular pressure (IOP) reduction of 31.1% was observed at 6-12 months. In studies reporting longer-term outcomes, the weighted mean IOP reduction was 30.4% and 32.9% at 36-48 months and 60 months, respectively. The pooled weighted mean IOP reduction from baseline across all studies at 6-12 months and 36-60 months post-stent implantation was 7.0 mmHg and 6.6 mmHg, respectively. Medication burden was reduced by approximately 1.0 medication at 6-18 months, and by 1.2 medications at 36-60 months.\n<\/p>\n<p>\n\u201cSince the inception of Glaukos Corporation, our goal has been to transform the treatment of chronic, debilitating eye diseases through development of novel, sustainable therapies,\u201d said Thomas Burns, Glaukos president and chief executive officer. \u201cScientific evidence and clinical rigor have been at the heart of our organization, with the earliest publication on <i>iStent<\/i> for the treatment of glaucoma dating back to 2002, two years prior to the initiation of the original <i>iStent<\/i> pivotal trial. Nearly 20 years later, we apply this same rigor and integrity to our business as we remain focused on generating strong clinical evidence, demonstrated by this trailblazing accomplishment of 200 peer-reviewed publications. I am grateful for our customers and employees around the world who have poured countless hours into this market-leading achievement to support our <i>iStent<\/i> technologies for the benefit of patients worldwide.\u201d\n<\/p>\n<p>\n\u201cAs one of the early adopters and investigators in the original <i>iStent<\/i> pivotal trial, I have experienced first-hand how <i>iStent, <\/i>as the first MIGS device<i>, <\/i>has fundamentally revolutionized the way we treat glaucoma today,\u201d said Thomas W. Samuelson, MD, surgeon at Minnesota Eye Consultants, and Adjunct Professor at the University of Minnesota. \u201cGlaukos has been focused on generating high-quality clinical evidence to support the uptake of MIGS procedures since day 1 and has continued to do so over the last 20 years. I am looking forward to Glaukos\u2019s continued innovation and exciting new product launches ahead.\u201d\n<\/p>\n<p>\n\u201cEach evolution, from <i>iStent<\/i> to <i>iStent inject<\/i> and now to <i>iStent inject W<\/i>, has been a transition to making the procedure more predictable and effective,\u201d said Ike Ahmed, MD, Research Director at the Kensington Eye Institute and Director of the Glaucoma and Advanced Anterior Segment Surgery Fellowship Program at the University of Toronto. \u201cIn my practice, <i>iStent<\/i> and <i>iStent inject<\/i> clinical outcomes have stood the test of time as I routinely see patients over 10 years post-<i>iStent<\/i> surgery whose glaucoma is still well-managed. The high safety and versatility of <i>iStent<\/i> technologies make this our most commonly used MIGS procedure in mild-moderate open-angle glaucoma.\u201d\n<\/p>\n<p>\nGlaukos remains dedicated to innovation and bringing customers around the world best-in-class technologies to serve their patients, continuing to invest upwards of 30% of revenue back into R&amp;D, including new product development. A significant number of clinical studies for both current and future products are ongoing, with additional studies commencing in the near future.\n<\/p>\n<p><b>About Glaukos <\/b><\/p>\n<p>\nGlaukos (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.glaukos.com&amp;esheet=52480128&amp;newsitemid=20210823005049&amp;lan=en-US&amp;anchor=www.glaukos.com&amp;index=1&amp;md5=f686ed5e89096d10981455b54f5eccf7\">www.glaukos.com<\/a>) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the <i>iStent<\/i>, its first MIGS device, in the United States in 2012, its next-generation <i>iStent inject<\/i> device in the United States in 2018, and most recently, the <i>iStent inject W <\/i>device in 2020. In corneal health, Glaukos\u2019 proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.\n<\/p>\n<p><b>Forward-Looking Statements <\/b><\/p>\n<p>\nAll statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the timing and extent to which obtain regulatory approval for investigational products, our ability to successfully commercialize such products, the ability to obtain and maintain adequate financial coverage and reimbursement for our products, and the continued efficacy and safety profile of our products as might be suggested in these publications. These and other risks, uncertainties and factors related to Glaukos and our business are described in detail under the caption \u201cRisk Factors\u201d and elsewhere in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, which was filed with the Securities and Exchange Commission (SEC) on August 5, 2021, and our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 1, 2021. Our filings with the Securities and Exchange Commission are available in the Investor Section of our website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.glaukos.com&amp;esheet=52480128&amp;newsitemid=20210823005049&amp;lan=en-US&amp;anchor=www.glaukos.com&amp;index=2&amp;md5=363771b65e2385a84ca699ea4fe8c2e9\">www.glaukos.com<\/a> or at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52480128&amp;newsitemid=20210823005049&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=2dd7e75cf35416b970a416936d179c4c\">www.sec.gov<\/a>. In addition, information about the risks and benefits of our products is available on our website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.glaukos.com&amp;esheet=52480128&amp;newsitemid=20210823005049&amp;lan=en-US&amp;anchor=www.glaukos.com&amp;index=4&amp;md5=8de1349464d4f796d91b1b95e5e0e377\">www.glaukos.com<\/a>. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210823005049r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210823005049\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210823005049\/en\/<\/a><\/span><\/p>\n<p>\nMedia Contact:<br \/>\n<br \/>Cassandra Dump<br \/>\n<br \/>(619) 971-1887<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Cassy@pascalecommunications.com\">Cassy@pascalecommunications.com<\/a><\/p>\n<p>\nInvestor Contact:<br \/>\n<br \/>Chris Lewis<br \/>\n<br \/>Sr. Director, Investor Relations &amp; Corporate Strategy &amp; Development<br \/>\n<br \/>(949) 481-0510<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:clewis@glaukos.com\">clewis@glaukos.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Medical Devices Health Surgery Pharmaceutical Optical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies Supporting the Most Robust, Diverse and Longest-Term Body of Clinical Evidence for Any MIGS Technology Multiple 5-, 6-, 7- and 8-Year Real-World Studies Published, Demonstrating Leading Efficacy &amp; Safety Across the Entire Glaucoma Disease Spectrum Outcomes Reinforce the Powerful Benefit\/Risk Calculus of iStent Technologies\u2019 Micro-invasive, Tissue-Sparing Approach, Supporting the More Than 800,000 iStent Procedures Performed Globally to Date SAN CLEMENTE, Calif.&#8211;(BUSINESS WIRE)&#8211; Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today an unprecedented clinical data milestone of 200 peer-reviewed publications highlighting the efficacy and safety of iStent\u00ae technologies around the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-530287","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies Supporting the Most Robust, Diverse and Longest-Term Body of Clinical Evidence for Any MIGS Technology Multiple 5-, 6-, 7- and 8-Year Real-World Studies Published, Demonstrating Leading Efficacy &amp; Safety Across the Entire Glaucoma Disease Spectrum Outcomes Reinforce the Powerful Benefit\/Risk Calculus of iStent Technologies\u2019 Micro-invasive, Tissue-Sparing Approach, Supporting the More Than 800,000 iStent Procedures Performed Globally to Date SAN CLEMENTE, Calif.&#8211;(BUSINESS WIRE)&#8211; Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today an unprecedented clinical data milestone of 200 peer-reviewed publications highlighting the efficacy and safety of iStent\u00ae technologies around the &hellip; Continue reading &quot;Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-23T11:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210823005049r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies\",\"datePublished\":\"2021-08-23T11:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\\\/\"},\"wordCount\":1369,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210823005049r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\\\/\",\"name\":\"Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210823005049r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-08-23T11:03:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210823005049r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210823005049r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/","og_locale":"en_US","og_type":"article","og_title":"Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies - Market Newsdesk","og_description":"Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies Supporting the Most Robust, Diverse and Longest-Term Body of Clinical Evidence for Any MIGS Technology Multiple 5-, 6-, 7- and 8-Year Real-World Studies Published, Demonstrating Leading Efficacy &amp; Safety Across the Entire Glaucoma Disease Spectrum Outcomes Reinforce the Powerful Benefit\/Risk Calculus of iStent Technologies\u2019 Micro-invasive, Tissue-Sparing Approach, Supporting the More Than 800,000 iStent Procedures Performed Globally to Date SAN CLEMENTE, Calif.&#8211;(BUSINESS WIRE)&#8211; Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today an unprecedented clinical data milestone of 200 peer-reviewed publications highlighting the efficacy and safety of iStent\u00ae technologies around the &hellip; Continue reading \"Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-23T11:03:06+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210823005049r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies","datePublished":"2021-08-23T11:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/"},"wordCount":1369,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210823005049r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/","name":"Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210823005049r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-08-23T11:03:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210823005049r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210823005049r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent\u00ae Technologies"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/530287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=530287"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/530287\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=530287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=530287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=530287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}